STIM biotech catalysts & pipeline

NEURONETICS INC · Data as of 2026-10-25

Upcoming catalysts

COMP360 — Regulatory decision

Late 2026

COMP360 psilocybin for MDD First-ever psychedelic offering for depression · Existing Compass Pathways collaboration Phase 3 trial complete FDA decision expected year-end 2026 Preparing 2027 commercial rollout Additional psychedelic-class therapies in development TRD, including post-traumatic stress disorder and anxiety

Source filing

COMP360 — NDA/BLA submission

by year-end

Compass has completed two Phase 3 studies demonstrating clinically meaningful and durable improvement through at least 26 weeks after just one or two doses, and plans to submit an NDA with the potential for an FDA decision by year-end.

Source filing

Explore the free biotech catalyst calendar